Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. announced the successful conclusion of its 2024 annual general meeting and related shareholder meetings held on June 12, 2025. All proposed resolutions, including the approval of the company’s financial statements, profit distribution plan, and final dividend for 2024, were passed with significant majority votes. This outcome reflects strong shareholder support and positions the company favorably for continued growth and stability in the pharmaceutical sector.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the distribution and retail of pharmaceutical and healthcare products. The company focuses on providing comprehensive healthcare services and solutions, with a significant market presence in China.
Average Trading Volume: 7,869,082
Technical Sentiment Signal: Sell
Current Market Cap: HK$59.38B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.